First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 611 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR ΚΑΡΚΙΝΟΣ ΠΑΧΕΩΣ ΕΝΤΕΡΟΥ February 10, 2019 2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast... July 27, 2023 Julia Louis-Dreyfus Talks About The Side Effects of Chemotherapy May 3, 2019 ctDNA Sequencing Reliably Detects KIT/PDGFRA Mutations and Correlates with Outcomes in... May 23, 2023 Load more HOT NEWS Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or... Promising Signal of Efficacy for Adjuvant Nivolumab in Patients with Completely... Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or... ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)
